Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Bipolar Disorder

Bipolar Disorder

Bipolar disorder is a chronic mental health condition marked by significant mood fluctuations, including episodes of mania and depression. Elevated energy levels, heightened mood or irritability, impulsive behavior, reduced sleep needs, rapid speech, racing thoughts, inflated self-esteem, and distractibility characterize mania. Individuals with bipolar disorder often alternate between depressive and manic states, with periods of emotional stability lasting an average of six months to a year.

Mania and Antimanic Drugs: Overview

Mania and Antimanic Drugs: Overview

Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as a...

Depression: Overview

Depression: Overview

Depression is a prevalent mental illness marked by persistent sadness and lack of interest in previously enjoyable activities. It can take several forms, including major depression, persistent depressive disorder, and bipolar I and II disorders. Symptoms range from emotional changes like chronic worry to physical changes like sleep disturbances and suicidal thoughts. From a neurobiological perspective, depression is believed to be triggered by abnormalities in the brain's prefrontal cortex,...

Antidepressant Drugs: MAOIs and Other Agents

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...

Depressive Disorders: MDD and Dysthymia

Depressive Disorders: MDD and Dysthymia

Depressive disorders are a group of mental health conditions characterized by pervasive feelings of sadness, diminished pleasure in life, and a significant impact on daily functioning. These conditions are most prevalent in individuals during their 30s and affect women at twice the rate of men. Contrary to popular belief, younger individuals are generally more susceptible to these disorders than older adults. Two key types of depressive disorders include Major Depressive Disorder (MDD) and...

Long-term Depression

Long-term Depression

Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Brain correlates of cognitive reserve in offspring of patients with schizophrenia or bipolar disorder.

European child & adolescent psychiatry·2026

Same author

The Prevalence of Obstructive Sleep Apnoea in Schizophrenia, Bipolar Disorder and Major Depressive Disorder: A Systematic Review With Meta-Analysis.

Acta psychiatrica Scandinavica·2026

Same author

20-year pharmacological treatment trajectories in a cohort of patients with bipolar disorder.

Psychiatry research·2026

Same author

Dot the i's and cross the t's: Can we get resilience in bipolar disorder right, please?

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology·2026

Same author

Cognitive reserve in non-affective first-episode psychosis: contributions of polygenic scores, early clinical features, and environment.

Psychological medicine·2026

Same author

Seasonal longitudinal effects of winter birth on psychopathology, cognition, and functioning in schizophrenia-spectrum and affective disorders: Findings from the PsyCourse Study.

Journal of affective disorders·2026

Search research articles

Related Experiment Video

Updated: Jun 2, 2026

Evaluating the Anti-depression Effect of Xiaoyaosan on Chronically-stressed Mice

Evaluating the Anti-depression Effect of Xiaoyaosan on Chronically-stressed Mice

Published on: January 7, 2019

Mania and depression. Mixed, not stirred.

Isabella Pacchiarotti¹, Lorenzo Mazzarini, Giorgio D Kotzalidis

¹Bipolar Disorders Program, Institute of Neurosciences, Hospital Clinic Barcelona, IDIBAPS, CIBERSAM, University of Barcelona, Barcelona, Catalonia, Spain.

Journal of Affective Disorders

|April 26, 2011

Summary

Patients exclusively experiencing mixed bipolar episodes exhibit higher suicide risk and comorbidity. Current diagnostic criteria for mixed episodes are insufficient, necessitating an expanded concept of "mixicity" across bipolar disorder subtypes.

More Related Videos

Developing a Rat Model for Bipolar Disorder

Developing a Rat Model for Bipolar Disorder

Published on: May 2, 2025

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

Related Experiment Videos

Last Updated: Jun 2, 2026

Evaluating the Anti-depression Effect of Xiaoyaosan on Chronically-stressed Mice

Evaluating the Anti-depression Effect of Xiaoyaosan on Chronically-stressed Mice

Published on: January 7, 2019

Developing a Rat Model for Bipolar Disorder

Developing a Rat Model for Bipolar Disorder

Published on: May 2, 2025

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

Area of Science:

Psychiatry
Clinical Psychology

Background:

Current diagnostic criteria for mixed bipolar episodes are limited, primarily focusing on Bipolar I disorder.
This limitation hinders understanding and appropriate classification of a significant patient population with mixed (hypo)manic-depressive features.

Purpose of the Study:

To investigate the existence of a bipolar-mixed continuum.
To compare clinical and demographic characteristics across three distinct groups of bipolar inpatients based on their history of manic and mixed episodes.

Main Methods:

134 Bipolar I inpatients were categorized into three groups: purely manic (PMA), mixed manic and mixed (MIX), and exclusively mixed (PMIX) episodes.
Statistical analyses included chi-square tests, one-way ANOVA, Tukey's post-hoc comparisons, and logistic regression.

Main Results:

The exclusively mixed episode group (PMIX) showed a higher prevalence of depressive polarity and fewer psychotic symptoms.
PMIX patients had a greater history of antidepressant use, suicide attempts, and Axis I comorbidity compared to the purely manic group (PMA).

Conclusions:

The exclusively mixed episode group (PMIX) presents elevated risks for suicide and comorbidities.
Existing DSM-IV-TR criteria inadequately classify these patients, potentially impacting treatment decisions.
The concept of 'mixicity' in bipolar disorder requires broader application beyond Bipolar I.